Successful idiotypic vaccination following stem cell allotransplant in lymphoma

Ascensión López-Dı́az de Cerio(Complejo Hospitalario de Navarra), Maurizio Bendandi(Universidad de Navarra), Mario Martínez Soldevilla(Center for Orthopaedics), Susana Inogés(Universidad de Navarra), Fernando Pastor(Navarre Institute of Health Research), Helena Villanueva(Center for Orthopaedics), Weiyun Z. Ai(City College of San Francisco), Elena Soria(Instituto de Biomedicina de Sevilla)
Leukemia & lymphoma/Leukemia and lymphoma
August 17, 2012
10.3109/10428194.2012.721544
Cited by 3

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247